Akili (AKLI) Total Stockholders Equity : $58.53 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Akili Total Stockholders Equity?

Akili's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $58.53 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Akili's Book Value per Share for the quarter that ended in Dec. 2023 was $0.75. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Akili's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.26.

Akili Total Stockholders Equity Historical Data

The historical data trend for Akili's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akili Total Stockholders Equity Chart

Akili Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

-82.25

-104.90

65.76

110.68

58.53

Akili Quarterly Data
	Dec19	Sep20	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial								110.68	92.44	82.96	69.09	58.53

Akili (NAS:AKLI) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Akili's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(58.532	-	0)	/	78.3565
	=	0.75

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Akili's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8.256	+	7.229)	/	58.532
	=	0.26

Akili Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Akili's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Akili (AKLI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Akili Inc (NAS:AKLI) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

AKLI:Mexico

Address

125 Broad Street, Fifth Floor, Boston, MA, USA, 02110

Website

https://www.akiliinteractive.com

Akili Inc is a digital medicine company pioneering the development of cognitive treatments through game-changing technologies.

Executives

Jacqueline Studer	officer: Chief Legal Officer	IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
Matthew Franklin	officer: See Remarks	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Martucci Walter Edward Ii	director, officer: Chief Executive Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Santosh Shanbhag	officer: Chief Financial Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Chamath Palihapitiya	director, 10 percent owner	THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Mary Hentges	director	C/O SHOTSPOTTER, INC., 7979 GATEWAY BLVD., STE. 210, NEWARK CA 94560
Tls Beta Pte. Ltd.	10 percent owner	60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Temasek Holdings (private) Ltd	10 percent owner	60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Fullerton Management Pte Ltd	10 percent owner	60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Anil Jina	officer: Chief Medical Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Temasek Life Sciences Private Ltd	10 percent owner	60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Jonathan David	officer: Chief Product Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Kenneth Ehlert	director	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Christine Lemke	director	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Adam Gazzaley	director	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110